Peter Hirth - 25 Jun 2025 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Reporting relationship: Director
Issuer ticker: ALGS
Reported as of: 25 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Jun 2025, 16:30:36 UTC
Prior SEC filing: 06 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Lesley Ann Calhoun, as attorney-in fact for Peter Hirth

Key filing fact

Peter Hirth filed Form 4 for Aligos Therapeutics, Inc. (ALGS) on 26 Jun 2025.

Key facts

This page summarizes Peter Hirth's Form 4 filing for Aligos Therapeutics, Inc. (ALGS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 Jun 2025, 16:30.

Change

Previous filing in this sequence was filed on 06 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001813780 Primary reporting owner

Hirth Peter

Relationship: Director
Address: C/O ALIGOS THERAPEUTICS, INC., 1 CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO
Signature: /s/ Lesley Ann Calhoun, as attorney-in fact for Peter Hirth
Signature date: 26 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALGS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +5,860
Change %
Price: $0.000000
Shares after: 5,860
Date: 25 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,860
Exercise price: $7.63
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2026 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.